Loading...
Market
UroGen Pharma Q4 2024 revenue
5
Resolution / Starting Odds
Below $50 million • 33%
$50 million to $100 million • 33%
Above $100 million • 34%
Company's quarterly financial reports
Story
UroGen Pharma Stock Halted, Up 50% After 82.3% Response in Trial
Jun 13, 2024, 03:16 PM
UroGen Pharma's stock ($URGN) was halted after announcing unprecedented results from its ENVISION trial. The trial showed an 82.3% duration of response at 12 months for UGN-102, a potential first FDA-approved non-surgical treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Following the announcement, $URGN stock spiked 50%, with a trading volume of 5.5 million, 15 times the average daily volume.
View original story
Similar markets
Below $100M • 33%
$100M-$200M • 33%
Above $200M • 33%
Less than 5% • 25%
5%-10% • 25%
10%-15% • 25%
More than 15% • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
